Kura Oncology (KURA) closed at $7.27 on November 6, 2026, up 6.9% from the previous close, on volume of 2,940,940 shares (30-day average 1,838,047).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 15, 2026 | Diagonal Call Spread | 15-Jan : 16-Apr-2712 : 10 C | 688 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 6-Nov 7:30 AM ET)
Analysts’ Top Healthcare Picks: Kura Oncology (KURA), Geron (GERN)
TipRanks (Thu, 5-Nov 8:02 AM ET)
Wedbush Sticks to Their Buy Rating for Kura Oncology (KURA)
TipRanks (Thu, 5-Nov 7:56 AM ET)
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
Globe Newswire (Wed, 4-Nov 9:02 AM ET)
Kura Oncology to Report Third Quarter Financial Results on November 10
Globe Newswire (Tue, 3-Nov 6:58 AM ET)
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
Globe Newswire (Tue, 13-Oct 7:30 AM ET)
Globe Newswire (Wed, 7-Oct 7:15 AM ET)
Globe Newswire (Tue, 29-Sep 5:15 AM ET)
Globe Newswire (Wed, 9-Sep 7:00 AM ET)
Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer
Globe Newswire (Tue, 8-Sep 7:00 AM ET)
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
Kura Oncology trades on the NASDAQ stock market under the symbol KURA.
As of November 6, 2026, KURA stock price climbed to $7.27 with 2,940,940 million shares trading.
KURA has a beta of 2.22, meaning it tends to be more sensitive to market movements. KURA has a correlation of 0.16 to the broad based SPY ETF.
KURA has a market cap of $646.74 million. This is considered a Small Cap stock.
Last quarter Kura Oncology reported $21 million in Revenue and -$.77 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.11.
In the last 3 years, KURA traded as high as $24.17 and as low as $5.41.
The top ETF exchange traded funds that KURA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
KURA has underperformed the market in the last year with a price return of -28.4% while the SPY ETF gained +10.8%. KURA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.7% and -24.3%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
KURA support price is $6.49 and resistance is $7.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KURA shares will trade within this expected range on the day.
